Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep1312 | Thyroid (non-cancer) | ECE2017

Treatment choice and patient satisfaction in thyrotoxicosis

Conaglen Helen , Tamatea Jade , Swarbrick Mark , Conaglen John , Elston Marianne

Background: Thyrotoxicosis may be associated with considerable patient morbidity. Graves’ disease (GD) and toxic multinodular goitre (TMNG) are the most common causes of thyrotoxicosis. Therapeutic options include anti-thyroid medication or definitive treatment by radioiodine or surgery. Efficacy, quality of life and cost-effectiveness are among the outcomes that have been compared between these two therapies. However, there is still no clear consensus as to which treatme...

ea0029p1060 | Male Reproduction | ICEECE2012

Testosterone replacement therapy: A comparison of testosterone mixed esters, extended release testosterone implants and testosterone undecanoate depot

Conaglen Helen M. , Yarndley Tania , Kamp Jozef , Paul Ryan G , Nirmalaraj Kingsley , Elston Marianne S , Conaglen John V

Introduction: Male hypogonadism is one of the most common endocrine disorders affecting 5.6% of men aged between 30–79 years. Testosterone deficiency (TD) is an independent risk factor for multiple cardiovascular risk factors including obesity, diabetes mellitus, hypertension, dyslipidaemia and endothelial dysfunction. The aims of testosterone replacement treatment (TRT) in hypogonadism are to improve or ameliorate the clinical features and to restore the serum T to physi...